The first oral GLP-1 Novonodisc's Rybelsus was approved

Take Semaglutide once a day PO

The world's first oral GLP-1 analog has landed in Korea.

 

Novonodisk announced on the 3rd that it has obtained an item license from the MFDS for oral GLP-1 analog-based type 2 diabetes treatment Rybelsus (Semaglutide).

 

Rybelsus is used as a dietary and exercise therapy supplement to improve blood sugar control in adults who do not have sufficient control of type 2 diabetes.

 

It is taken once a day, and there is no need to control the dosage of drugs in patients with renal or hepatic dysfunction or in the elderly.

 

Rybelsus demonstrated its validity and safety in eight global clinical studies PIONEER.

 

In particular, it showed a superior blood glucose drop effect than the SGLT-2 inhibitor-based Empagliflozin and DPP-4 inhibitor-based Sitagliflozin, which are representative oral treatments.

 

The advantage of weight control compared to Sitagliptin was also confirmed.

 

In a PIONEER2 study of patients whose blood sugar is not controlled by Metformin, the Rybelsus group confirmed a 1.3% decrease in glycated hemoglobin level compared to the baseline, which is superior to -0.9% of the Empagliflozin group.

 

PIONEER9 and PIONEER10 studies have demonstrated efficacy in Asians.

 

This is a clinical trial conducted on 458 patients with type 2 diabetes whose blood sugar is not controlled by administration of oral hypoglycemia alone.

 

In the change in glycated hemoglobin levels at week 52, the Rybelsus-administered group was -1.7%, which was superior to the Dulaglutide-administered group of -1.4%.

 

Rana Azfar Zafar, president of Novonodisk, said, "Rybelsus is expected to establish itself as an innovative treatment option for adult diabetes patients with type 2 based on the incidental benefits of excellent blood sugar drop and weight control identified through large-scale clinical trials."